Abeona Therapeutics Inc. (ABEO) AI Stock Analysis

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical firm specializing in the development of gene and cell therapies aimed at addressing life-threatening rare genetic diseases. Established in 1974 and based in New York, New York, the company is advancing several clinical candidates. Its flagship program is EB-101, an autologous cell therapy currently in Phase III clinical trials for recessive dystrophic epidermolysis bullosa. Abeona is also progressing ABO-102 for Sanfilippo syndrome type A, ABO-201 for CLN3 disease, ABO-401 for cystic fibrosis, and ABO-50X for genetic eye disorders, all built using its AIM vector platform.

Abeona's annual revenue rose 66.3% to $5.8M in FY2025 from $3.5M in FY2023, following prior declines in FY2021 and FY2022. The 5-year revenue CAGR from FY2018 to FY2025 stood at 14.2%. Net income reached $71.2M in FY2025, primarily driven by non-operating factors, as operating margin remained negative at -1536.9% alongside an EPS of -$1.19. Research and development expense totaled $26.8M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $25.5M with an EPS of -$1.18. In the quarter ended June 30, 2026, quarterly revenue grew 2745.0% year-over-year.

As of June 30, 2026, Abeona held $146.8M in cash and short-term investments against total debt of $19.9M, resulting in a net cash balance of $127.0M. The company's current ratio stood at 6.63, with a debt-to-equity ratio of 0.16 and shareholders' equity of $128.1M. Operating cash flow in FY2025 was -$76.3M, and free cash flow was -$84.3M, which included capital expenditures of $8.0M. Over the five-year period, Abeona's share count increased by 1262.2%.

Abeona trades at an enterprise value of $189.3M and a market capitalization of $253.3M. Its forward P/E ratio is 18.7x, compared to 17.3x for the median of its US-listed Healthcare peers. The company's price-to-sales multiple is 9.9x, above the peer median of 4.1x, while its EV/EBITDA stands at 3.8x compared to the peer median of 12.0x. Over the past year, Abeona shares fell 19.0%, underperforming the S&P 500 (SPY), which gained 16.8%. Over a 5-year period, the stock declined 80.5% against an 83.0% gain for the benchmark.

All 7 analysts covering Abeona assign the stock a Strong Buy rating. The mean price target is $18.88, which is 326.1% above its last close of $4.43. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.95 and revenue of $52.6M. For the following fiscal year, 4 analysts project revenue of $115.6M, representing growth of 119.7%, alongside an EPS of -$0.21. Over the last four quarters, the company beat EPS estimates 2 times. The next earnings date is scheduled for November 11, 2026.

This page is an AI-written research summary of Abeona Therapeutics Inc. (ABEO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ABEO income statement, ABEO balance sheet, ABEO key metrics, ABEO analyst forecast, ABEO chart. See the ABEO stock overview for the latest quote and news.